ClinicalTrials.gg
RecruitingNCT05857709Understand-CFUpdated May 18, 2023

Fitness, Body Composition, Physical Activity and Sleep Patterns in People With Cystic Fibrosis on Modulator Therapy.

An observational study in Cystic Fibrosis, sponsored by University of Portsmouth. Recruiting at 1 site in United Kingdom. Open to participants aged 10 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-18.

Sponsored by University of Portsmouth · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
100
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Cystic Fibrosis with a site in United Kingdom — 21 open to participants now, 32 under way, 4 of them phase 3. Cystic Fibrosis · United Kingdom.

Planned enrollment
19th of 49
100 · median 79
Started
2023
with 11 others
Observational
49 of 236
14 open now
Primary completion
2024-02
later than 2 of 31 live
Registered
200th of 236
by date

Among the 236 studies in Cystic Fibrosis with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 49 observational ones that give a count, is one of 12 that started in 2023, is one of 49 observational ones, reaches primary completion later than 2 of the 31 other live ones, and was the 200th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

21 of the 236 studies in Cystic Fibrosis with a site in United Kingdom are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 10 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Cystic Fibrosis with a site in United Kingdom, or all of them as a file.
02

Study summary

Cystic fibrosis (CF) is the most common inherited condition in the United Kingdom, affecting approximately 10,837 people. It is well recognised that regular exercise is clinically important for people with CF. Exercise function measured by the maximal oxygen consumption during a cardiopulmonary exercise test is often reduced in people with CF and this has been attributed to multiple factors including, altered heart and blood vessel function, muscle function, reduced physical activity levels and poorer sleep quality.

New medicine (modulators) have become available for many people with CF. Modulators appear able to reduce sweat chloride concentrations, improve lung function and reduce the frequency of pulmonary exacerbations in people with CF. Little evidence exists to show how they may have changed the fitness and underlying mechanisms responsible for this in people with CF.

This study aims to:

  1. determine the exercise function
  2. determine the blood vessel function
  3. determine body composition
  4. determine physical activity and sleep levels in people with CF on modulator therapy compared to a healthy controls group.
Read the detailed description

CF is the most common inherited condition in the United Kingdom, affecting approximately 10,837 people. CF affects the movement of salt and water across the body which leads to a thick sticky build up of mucus causing problems in the lungs and digestive system. CF also causes problems in other parts of the body for example, the heart, the blood vessels and muscles. This can impact a person with CFs' ability to exercise which can have impact prognosis, quality of life and increase the amount of times someone with CF is admitted to hospital due to a chest infection.

For many people with CF, new medicine (modulators) have lately become accessible bringing big changes to their health. Elexacaftor-tezacaftor-ivacaftor (ETI) is the most recently approved modulator for use in people with specific CF transmembrane conductance regulator gene mutations and is now the most widely used modulator therapy. So far clinical trials have largely looked at lung function, sweat chloride levels and body mass index. The wider reaching effects of modulator therapy on exercise function has not been studied. This study will see if people with CF have blood vessel and exercise dysfunction, abnormal body composition and reduced physical activity and sleep quality when they are taking modulator therapy compared to a healthy group.

The aims of this study are:

  1. Determine the aerobic exercise function and mechanisms underlying this in people with CF stable on ETI and whether this is different to healthy age- and sex-matched controls;
  2. Determine the peripheral muscle function in people with CF stable on ETI and whether this is different to healthy age- and sex-matched controls;
  3. Determine the functional exercise capacity in people with CF stable on ETI and whether this is different to healthy age- and sex-matched controls;
  4. Determine the micro- and macrovascular endothelial function in people with CF stable on ETI and whether this is different to healthy age- and sex-matched controls;
  5. Determine body composition in people with CF stable on ETI and whether this is different to healthy age- and sex-matched controls;
  6. Determine the physical activity levels and sleep duration and quality in people with CF stable on ETI and whether this is different to healthy age- and sex-matched controls

This study will recruit 50 people with CF and 50 healthy age- and sex-matched control participants who are older than 10 years of age. It will ask them to attend the University of Portsmouth for 2 visits. The first visit will last \~3 hours. During this time they will undergo measures on blood vessel function and aerobic exercise function. The second visit will last \~2 hours. During this time they will undergo a body composition scan and a series of muscle function test. At home, participants will wear an accelerometer for 7 days and complete a series of questionnaires.

03

Conditions studied

  • Cystic Fibrosis

Keywords

  • Exercise
  • Modulator therapy
  • Peripheral muscle function
  • Vascular function
  • Body composition
  • Physical activity
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be recruited from adult and paediatric CF outpatient clinics within the Southampton CF network.

Eligibility criteria

Inclusion criteria for participants with cystic fibrosis:

  • Stable on the modulator therapy, Kaftrio®
  • Males and females ≥ 10 years of age
  • CF diagnosis based on clinical features, supported by a history of an abnormal sweat test (sweat chloride > 60 mmol·L-1 > 100 mg sweat), where possible, diagnostic genotyping would also be desired
  • Can clearly state that they are not pregnant
  • No to performing exercise
  • Can understand and cooperate with the study protocol
  • No increase in symptoms or weight loss in the preceding 2 weeks

Inclusion criteria for healthy control participants:

  • Healthy males and females who are age- and sex-matched to the enrolled individuals with CF
  • Can clearly state that they are not pregnant
  • No clinical diagnosis of a chronic disease
  • Can understand and cooperate with the study protocol
  • No contraindications to performing exhaustive exercise

Exclusion criteria for participants with cystic fibrosis:

  • Any non-pulmonary conditions that may impair exercise ability, such as musculoskeletal disorders and cardiovascular disease.
  • Unstable co-morbid asthma (daily pulmonary function variability of >20%)
  • Is pregnant during the initial screening process
  • Unable to understand or cooperate with the study protocol due to learning difficulties or otherwise
  • Not of a suitable age for testing
  • Is a smoker or inhales any other substances
  • Are taking vasoactive medications

Exclusion criteria for healthy control participants:

  • Any pulmonary, metabolic or cardiovascular conditions
  • Any other diagnosed disease
  • Any non-pulmonary conditions that may impair exercise ability, such as musculoskeletal disorders and cardiovascular disease
  • Is pregnant during the initial screening procedure
  • Presents with co-morbidities to performing exhaustive exercise
  • Is a smoker or inhales any other substance
  • Unable to understand or cooperate with the study protocol due to learning difficulties or otherwise
  • Not an age- or sex-match for the CF group
  • Are taking vasoactive medications
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cystic fibrosis

    No intervention - only assessments.

  • Healthy Control

    No intervention - only assessments.

06

What researchers measure

Primary outcomes

  1. Maximal oxygen uptake

    Between group differences in maximal oxygen uptake derived from a maximal cardiopulmonary exercise testing on a cycle ergometer

    Time frame: Day 1 - baseline

Secondary outcomes

  1. Peak minute ventilation

    Between group differences in peak minute ventilation derived from a maximal cardiopulmonary exercise test on a cycle ergometer

    Time frame: Day 1 - baseline

  2. Oxygen uptake at the gas exchange threshold

    Between group differences in oxygen uptake at the gas exchange threshold derived from a maximal cardiopulmonary exercise test on a cycle ergometer

    Time frame: Day 1 - baseline

  3. Peak power output

    Between group differences in peak power output derived from a maximal cardiopulmonary exercise test on a cycle ergometer

    Time frame: Day 1 - baseline

  4. Time to exhaustion

    Between group differences in time to exhaustion derived from a maximal cardiopulmonary exercise test on a cycle ergometer

    Time frame: Day 1 - baseline

  5. Heart rate

    Between group differences in heart rate derived from a maximal cardiopulmonary exercise test on a cycle ergometer

    Time frame: Day 1 - baseline

  6. Near-infrared spectroscopy derived deoxygenated [haemoglobin + myoglobin]

    Between group differences in dynamics of near-infrared spectroscopy derived deoxygenated \[haemoglobin + myoglobin\]

    Time frame: Day 1 - baseline

  7. Cardiac output

    Between group differences in dynamics of non-invasive thoracic impedance cardiography

    Time frame: Day 1 - baseline

  8. Stroke volume index

    Between group differences in dynamics of non-invasive thoracic impedance cardiography

    Time frame: Day 1 - baseline

  9. Forced Expiratory Volume in the 1st second (% predicted)

    Between group differences in Forced Expiratory Volume in the 1st second measured using flow-volume loop spirometry

    Time frame: Day 1 - baseline

  10. Forced Vital Capacity (%predicted)

    Between group differences in Forced Vital Capacity measured using flow-volume loop spirometry

    Time frame: Day 1 - baseline

  11. Total minutes of physical activity (light, moderate, moderate to vigorous physical activity)

    Between group differences in physical activity assessed via wrist-worn accelerometery

    Time frame: Physical activity will be measured continuously for 7 days

  12. Sleep efficiency (time in bed + time asleep)

    Between group differences in sleep efficiency assessed via wrist-worn accelerometery

    Time frame: Sleep efficiency will be measured continuously for 7 days

  13. Acetylcholine iontophoresis

    Between group differences in acetylcholine iontophoresis measure of microvascular function

    Time frame: Day 1 - baseline

  14. Insulin iontophoresis

    Between group differences in insulin iontophoresis measure of microvascular function

    Time frame: Day 1 - baseline

  15. Percentage change in brachial artery diameter taken from the Flow Mediated Dilation assessment

    Between group differences in Flow Mediated Dilation assessment derived from baseline brachial artery diameter and peak brachial artery diameter from flow mediated dilation measure of macrovascular function

    Time frame: Day 1 - baseline

  16. Maximum quadricep strength

    Derived from a maximal voluntary contraction

    Time frame: Day 2 - baseline

  17. Quadricep fatigability index

    Derived from change in maximal voluntary contraction

    Time frame: Day 2 - baseline

  18. Handgrip strength

    Between group difference in handgrip strength

    Time frame: Day 2 - baseline

  19. Sit to stand repetitions per minute

    Between group difference in sit to stand repetitions per minute

    Time frame: Day 2 - baseline

  20. Body composition (total fat-free mass and total fat mass)

    Derived from dual-energy X-ray absorptiometry

    Time frame: Day 2 - baseline

  21. Habitual activity estimation scale

    Between group difference in habitual activity estimation scale - answers are varied and require numerical values, percentages and/or multiple choice questions

    Time frame: Day 2 - baseline

  22. Cystic fibrosis questionnaire revised

    Between group difference in health related quality of life on a 0 - 100 scale with higher scores indicating better health related quality of life

    Time frame: Day 2 - baseline

  23. The Pittsburgh Sleep Quality Index

    Between group differences in the Pittsburgh Sleep Quality Index on a 0 - 21 scale with higher scores indicating worse sleep quality

    Time frame: Day 2 - baseline

  24. Perceived exertion (breathing effort, chest tightness, throat narrowing, perceived exertion)

    Between group differences in perceived exertion using the Dalhousie Dyspnoea and Perceived Exertion Scales during a maximal cardiopulmonary exercise testing on a cycle ergometer on a 1 - 7 scale with a higher value indicating a worse perceived exertion

    Time frame: Day 1 - baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Feb 2024, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
May 15, 2023
StartActual
Jan 10, 2023
Primary completionEst.
Feb 2024
CompletionEst.
Feb 2024
Last update
May 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05857709
Lead sponsor
University of Portsmouth
Responsible party
Dr Zoe Saynor (Reader (Associate Professor) in Clinical Exercise Physiology, University of Portsmouth) — Principal investigator
First posted
May 15, 2023
Start date
Jan 10, 2023
Primary completion
Feb 2024 (estimated)
Completion
Feb 2024 (estimated)
Last update
May 18, 2023

Study contacts

Zoe Saynor
Contact
zoe.saynor@port.ac.uk
02392843080
Lauren Clayton
Contact
lauren.clayton@port.ac.uk
02392843085

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion